---
title: "BLRX: Full year 2025 results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280217686.md"
description: "BioLineRx Ltd. (NASDAQ: BLRX) reported its 2025 financial results, revealing license revenues of $1.2 million and a net operating loss of $10.3 million. The company announced that its joint venture with Hemispherian, Tetragon Biosciences, is set to begin patient screening for glioblastoma by the end of March 2026."
datetime: "2026-03-23T21:27:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280217686.md)
  - [en](https://longbridge.com/en/news/280217686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280217686.md)
---

# BLRX: Full year 2025 results

By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported 2025 financial and operational results in a March 23rd, 2026, press release. For the year, it produced license revenues of $1.2 million and a net operating loss of $10.3 million. The joint venture (JV) with Hemispherian, called Tetragon Biosciences, expects to begin screening patients by the end of this month for the glioblastoma...

### Related Stocks

- [BLRX.US](https://longbridge.com/en/quote/BLRX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [BioLineRx starts Phase 1/2a trial of GLIX1 in recurrent glioblastoma](https://longbridge.com/en/news/286900261.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings](https://longbridge.com/en/news/279901115.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)